About Aldo-keto reductase family 1 member D1
Aldo-keto reductase family 1 member D1 (AKR1D1) is a protein
from Homo sapiens identified by UniProt accession
P51857, 326 residues long.
MolForge cross-references it against 0 known binders and
72 disease associations.
Target properties
| Protein name | Aldo-keto reductase family 1 member D1 |
|---|
| UniProt accession | P51857 |
|---|
| Gene | AKR1D1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 326 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (72)
Diseases linked to this target (Open Targets).
- Congenital bile acid synthesis defect type 2 · score 0.77
- congenital bile acid synthesis defect 2 · score 0.72
- testosterone measurement · score 0.49
- liver failure · score 0.47
- Cholestasis · score 0.46
- cholestasis · score 0.46
- blood metabolite measurement · score 0.40
- monocyte count · score 0.33
- monocyte percentage of leukocytes · score 0.28
- lymphocyte:monocyte ratio · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P51857-F1 | alphafold | PREDICTED | 97.14 | — |
Amino-acid sequence (326 residues)
MDLSAASHRI PLSDGNSIPI IGLGTYSEPK STPKGACATS VKVAIDTGYR HIDGAYIYQN EHEVGEAIRE KIAEGKVRRE DIFYCGKLWA TNHVPEMVRP TLERTLRVLQ LDYVDLYIIE VPMAFKPGDE IYPRDENGKW LYHKSNLCAT WEAMEACKDA GLVKSLGVSN FNRRQLELIL NKPGLKHKPV SNQVECHPYF TQPKLLKFCQ QHDIVITAYS PLGTSRNPIW VNVSSPPLLK DALLNSLGKR YNKTAAQIVL RFNIQRGVVV IPKSFNLERI KENFQIFDFS LTEEEMKDIE ALNKNVRFVE LLMWRDHPEY PFHDEY
Explore Aldo-keto reductase family 1 member D1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets